Back to List View Graph View

Poly(ADP-ribose) polymerase 1 (PARP1)

Poly(ADP-ribose) polymerase 1 (PARP1) is an abundant nuclear enzyme and the cell's principal sensor of single-strand DNA breaks.

Where the papers sit

32 papers from the last 6 months study Poly(ADP-ribose) polymerase 1 (PARP1) directly · updated from PubMed 15 Nov 2026

Study type 0 clinical trials · 30 preclinical · 2 unclassified

Themes 5 themes · 1 paradigm shift · 1 new direction

  • PARP Inhibitor Development

    PARP inhibitor research is moving toward selective, CNS-penetrant, degradable, radiolabeled, and imaging-capable agents, while combination strategies address resistance. p300 inhibition, TopBP1 inhibition, and MSH6-linked repair biology are used to restore sensitivity, especially in BRCA-proficient or osimertinib-resistant settings. Talazoparib-induced cGAS/STING activation adds an innate-immune endpoint, and [211At]talazoparib extends PARP targeting into alpha-particle therapy. Olaparib conjugates support tumor imaging, whereas rucaparib is being tested against PARP1-mediated parthanatos in sepsis, broadening the application beyond oncology.

    10 papers · 31.2%

  • Homologous Recombination and PARP

    Homologous recombination deficiency remains the main route to PARP1 sensitivity, but the work is moving toward broader synthetic-lethal combinations. RAD51C variants, TBK1-mediated repair suppression, and BRD4–cJUN–CCL2 disruption are used to weaken HRR and improve therapeutic response. Dual PARP1/TOP1 or PARP/BRD4 inhibitors and new chemical scaffolds seek stronger tumor killing than olaparib alone, including in bladder cancer and triple-negative breast cancer. Whether these combinations improve selectivity and overcome repair-proficient resistance remains open.

    7 papers · 21.9%

  • PARP1-Targeted Cancer Therapy

    PARP1-directed cancer therapy is moving beyond single-agent inhibition toward degraders, dual-action molecules, and immune-activating combinations. Deoxypodophyllotoxin and camptothecin–niraparib constructs pair PARP1 blockade with tubulin or TOP1-associated cytotoxicity, while degraders are being developed for colon cancer. PARP inhibition is also being combined with T-cell receptor β-directed immunotherapy, and cepharanthine is linked to immunogenic cell death. The outlying UVA study connects USP10–SIRT6–PARP1 signaling to keratinocyte senescence and photoaging rather than tumor control.

    6 papers · 18.8%

  • Dual-Target PARP1 Inhibitors

    Structure-guided medicinal chemistry is combining PARP1 inhibition with EGFR or COX-2 blockade to seek broader anticancer activity. The reported programs emphasize hybrid scaffolds, including molecular boomerangs and imidazothiazole-hydrazone compounds, with olaparib serving as a reference. Molecular dynamics and enzyme or cell-based inhibition assays are used to connect substituent design with potency. The shared direction is early multi-target compound optimization, not clinical validation.

    2 papers · 6.2%

  • Others — PARP Biology and Therapeutics

    PARP biology is being pursued across cancer, neurodegeneration, spinal injury, kidney stones, and reproductive or mitochondrial dysfunction, with both inhibitors and degraders under study. Isoform-selective PARP1 agents and PARP1/2-focused compounds are being paired with mechanistic readouts such as NAD+ metabolism, mitochondrial quality control, p53 signaling, and parthanatos. Cancer work emphasizes BRCA-deficient selectivity, while noncancer studies test whether PARP-driven cell death can be reduced. Analytical method development appears alongside these therapeutic and disease studies, so no single clinical direction dominates.

    7 papers · 21.9%

PARADIGM SHIFT

PARP inhibitor efficacy depends on PARP1 trapping rather than catalytic inhibition alone

The Ewing sarcoma study and the acidic ovarian-cancer microenvironment study both challenge the assumption that catalytic PARP inhibition is sufficient for therapeutic activity: in Ewing sarcoma, talazoparib’s stronger PARP-trapping capacity, rather than inhibition alone, produced greater tumor control and innate immune activation than olaparib or veliparib 42392399Jul, while acidic ovarian-tumor conditions reduced PARP1 trapping and weakened PARP-inhibitor responses, with p300 blockade restoring sensitivity 42467549Jul. The account therefore shifts from treating PARP inhibition as a uniform mechanism to treating PARP1 trapping as a critical, context-dependent determinant of efficacy and resistance.

NEW DIRECTION

PARP1 functions as a mediator of microbiota-derived metabolite toxicity in calcium oxalate kidney-stone disease

The gut microbiota–isoallolithocholic acid axis in calcium oxalate nephrolithiasis instead identifies PARP1 as a direct effector of a microbial metabolite in renal stone formation, rather than primarily as a DNA-repair target in cancer or a marker and vehicle for PARP-directed therapy. Isoallolithocholic acid bound PARP1, and genetic or pharmacological PARP1 suppression reduced crystal deposition, tubular injury, and mitochondrial impairment in rat and mouse models; microbiota depletion or transplantation correspondingly altered the metabolite-driven phenotype. This places PARP1 within a causal gut–kidney pathway involving PARP1-mediated parthanatos and opens a disease application outside the categories represented by the other papers 42666033Aug.

Papers

The 32 papers from the last 6 months that study Poly(ADP-ribose) polymerase 1 (PARP1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

PARP Inhibitor Development (10)
  1. Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018572
  2. Inhibition of PARP1-mediated parthanatos by rucaparib phosphate alleviates sepsis-induced acute lung injury. International immunopharmacology · 12 Sept 2026 PMID 42731470
  3. Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. PloS one · 2 Sept 2026 PMID 42685115
  4. A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging. ChemMedChem · 20 Aug 2026 PMID 42619027
  5. Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Science advances · 5 Aug 2026 PMID 42555732
  6. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer research · 17 Jul 2026 PMID 42467549
  7. Versatile Detection of Cellular Protein via Fluorescence Anisotropy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Jul 2026 PMID 42439473
  8. Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma. Cancer letters · 2 Jul 2026 PMID 42392399
  9. Identification of XZ8078 as a Dual-Target Degrader Targeting PARP1 and IKZF3 for Broad Spectrum Anticancer Treatment. Journal of medicinal chemistry · 1 Jul 2026 PMID 42380731
  10. Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic. Molecular pharmaceutics · 8 Jun 2026 PMID 42257398
Homologous Recombination and PARP (7)
  1. Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 Axis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018612
  2. PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer. Journal for immunotherapy of cancer · 7 Oct 2026 PMID 42843923
  3. RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition. NAR cancer · 21 Aug 2026 PMID 42625895
  4. Inflammatory kinase TBK1 suppresses homologous recombination DNA repair to sensitize tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America · 14 Aug 2026 PMID 42599782
  5. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
  6. Structural Modification and Prodrug Design Based on Natural Stilbene Scaffold for the Discovery of Novel PARP-1 Inhibitors with Improved Antitumor Activity. Journal of medicinal chemistry · 20 Jul 2026 PMID 42475630
  7. Structure-Based Design, Synthesis, and Biological Evaluation of Oxadiazole-Morpholine Hybrids as Potent PARP-1 Inhibitors Inducing Apoptosis in Breast Cancer Cells. Drug development research · 8 Jul 2026 PMID 42418250
PARP1-Targeted Cancer Therapy (6)
  1. Rational design, synthesis, and biological evaluation of novel PARP1 degraders for colon cancer therapy. Bioorganic chemistry · 7 Aug 2026 PMID 42567124
  2. USP10-SIRT6-PARP1 axis drives keratinocyte senescence and skin photoaging under chronic UVA exposure. International immunopharmacology · 31 Jul 2026 PMID 42537350
  3. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  4. PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. Journal for immunotherapy of cancer · 1 Jul 2026 PMID 42386344
  5. Cepharanthine triggers immunogenic cell death in solid tumors by suppressing protein kinase C zeta-mediated poly(ADP-ribose) polymerase 1 expression and synergizes with immunotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology · 13 Jun 2026 PMID 42287818
  6. Discovery of novel N-heterocycle-fused deoxypodophyllotoxin analogues as dual tubulin/PARP1 inhibitors for cancer treatment. European journal of medicinal chemistry · 30 May 2026 PMID 42217374
Dual-Target PARP1 Inhibitors (2)
  1. Discovery of novel imidazo[2,1-b]thiazole-hydrazone hybrids as multi-target anticancer agents: Dual PARP-1/COX-2 inhibition and MetAP-2 modulation. Bioorganic chemistry · 4 Jun 2026 PMID 42242020
  2. Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
Others — PARP Biology and Therapeutics (7)
  1. Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 29 Aug 2026 PMID 42666033
  2. Targeting the PARP1-p53 Axis Could Mitigate Necrotic-Apoptotic Signaling and Secondary Neurodegeneration After Spinal Cord Injury. Molecular neurobiology · 28 Aug 2026 PMID 42665756
  3. Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593943
  4. Potent and isoform-selective PARP1 degraders for the treatment of BRCA-deficient cancers. Bioorganic chemistry · 8 Jul 2026 PMID 42419053
  5. A Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance. Chirality · 17 Jun 2026 PMID 42304726
  6. HM568 Enhances NAD+ Biosynthesis to Ameliorate Mitochondrial Dysfunction and Neurotoxicity in Parkinson's Disease Models: A Putative Link to PARP1 Modulation. Molecular neurobiology · 5 Jun 2026 PMID 42247013
  7. Prostaglandin D2 reinforces mitochondrial quality control to enhance ovarian and embryonic competence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 23 May 2026 PMID 42176571

By study type

Preclinical: animal, cell and lab studies (30)
  1. Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 Axis. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018612
  2. Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018572
  3. PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer. Journal for immunotherapy of cancer · 7 Oct 2026 PMID 42843923
  4. Inhibition of PARP1-mediated parthanatos by rucaparib phosphate alleviates sepsis-induced acute lung injury. International immunopharmacology · 12 Sept 2026 PMID 42731470
  5. Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. PloS one · 2 Sept 2026 PMID 42685115
  6. Targeting the PARP1-p53 Axis Could Mitigate Necrotic-Apoptotic Signaling and Secondary Neurodegeneration After Spinal Cord Injury. Molecular neurobiology · 28 Aug 2026 PMID 42665756
  7. RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition. NAR cancer · 21 Aug 2026 PMID 42625895
  8. A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging. ChemMedChem · 20 Aug 2026 PMID 42619027
  9. Inflammatory kinase TBK1 suppresses homologous recombination DNA repair to sensitize tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America · 14 Aug 2026 PMID 42599782
  10. Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593943
  11. Rational design, synthesis, and biological evaluation of novel PARP1 degraders for colon cancer therapy. Bioorganic chemistry · 7 Aug 2026 PMID 42567124
  12. Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Science advances · 5 Aug 2026 PMID 42555732
  13. USP10-SIRT6-PARP1 axis drives keratinocyte senescence and skin photoaging under chronic UVA exposure. International immunopharmacology · 31 Jul 2026 PMID 42537350
  14. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
  15. Structural Modification and Prodrug Design Based on Natural Stilbene Scaffold for the Discovery of Novel PARP-1 Inhibitors with Improved Antitumor Activity. Journal of medicinal chemistry · 20 Jul 2026 PMID 42475630
  16. Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. Cancer research · 17 Jul 2026 PMID 42467549
  17. A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
  18. Potent and isoform-selective PARP1 degraders for the treatment of BRCA-deficient cancers. Bioorganic chemistry · 8 Jul 2026 PMID 42419053
  19. Structure-Based Design, Synthesis, and Biological Evaluation of Oxadiazole-Morpholine Hybrids as Potent PARP-1 Inhibitors Inducing Apoptosis in Breast Cancer Cells. Drug development research · 8 Jul 2026 PMID 42418250
  20. Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma. Cancer letters · 2 Jul 2026 PMID 42392399
  21. PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. Journal for immunotherapy of cancer · 1 Jul 2026 PMID 42386344
  22. Identification of XZ8078 as a Dual-Target Degrader Targeting PARP1 and IKZF3 for Broad Spectrum Anticancer Treatment. Journal of medicinal chemistry · 1 Jul 2026 PMID 42380731
  23. A Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance. Chirality · 17 Jun 2026 PMID 42304726
  24. Cepharanthine triggers immunogenic cell death in solid tumors by suppressing protein kinase C zeta-mediated poly(ADP-ribose) polymerase 1 expression and synergizes with immunotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology · 13 Jun 2026 PMID 42287818
  25. Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic. Molecular pharmaceutics · 8 Jun 2026 PMID 42257398
  26. HM568 Enhances NAD+ Biosynthesis to Ameliorate Mitochondrial Dysfunction and Neurotoxicity in Parkinson's Disease Models: A Putative Link to PARP1 Modulation. Molecular neurobiology · 5 Jun 2026 PMID 42247013
  27. Discovery of novel imidazo[2,1-b]thiazole-hydrazone hybrids as multi-target anticancer agents: Dual PARP-1/COX-2 inhibition and MetAP-2 modulation. Bioorganic chemistry · 4 Jun 2026 PMID 42242020
  28. Discovery of novel N-heterocycle-fused deoxypodophyllotoxin analogues as dual tubulin/PARP1 inhibitors for cancer treatment. European journal of medicinal chemistry · 30 May 2026 PMID 42217374
  29. Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
  30. Prostaglandin D2 reinforces mitochondrial quality control to enhance ovarian and embryonic competence. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 23 May 2026 PMID 42176571
Unclassified: not yet indexed with MeSH (2)
  1. Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 29 Aug 2026 PMID 42666033
  2. Versatile Detection of Cellular Protein via Fluorescence Anisotropy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Jul 2026 PMID 42439473